IRWD NASDAQ
Ironwood Pharmaceuticals, Inc.
1W: -11.9%
1M: -17.5%
3M: -16.9%
YTD: -14.8%
1Y: +149.3%
3Y: -62.2%
5Y: -72.9%
$3.64
-0.12 (-3.19%)
Weekly Expected Move ±6.3%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (69)
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Break Above 200-Day Moving Average – Here’s What Happened
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $6.23 Average Target Price from Brokerages
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Ironwood (IRWD) Q2 2026 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates
Community Health Q2 Loss Wider Than Expected, 2026 View Lowered
UnitedHealth Tops Q2 Earnings on Cost Control, Raises '26 Outlook
Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stock
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
10 small-cap U.S. healthcare stocks with the strongest momentum grades
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?
Ironwood (IRWD) Q1 2026 Earnings Call Transcript
IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use
Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
Ironwood reiterates 2026 LINZESS guidance of $1.125B-$1.175B as STARS-2 initiation nears
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Ironwood Pharmaceuticals Non-GAAP EPS of $0.24, revenue of $106.5M
Strong Buy at under $10: The highest Quant-rated bargain stocks right now
Zacks Research Has Negative Estimate for IRWD Q2 Earnings
Zacks Research Has Bullish Forecast for IRWD Q4 Earnings
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of “Hold” by Brokerages
Top and lowest-rated small-cap stocks heading into earnings
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Passes Above Two Hundred Day Moving Average – Should You Sell?
As investors rotate out of mega caps, these 10 small-cap Strong Buys are worth watching
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock?
Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) PT at $4.93
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?
Top 10 undervalued small-cap stocks with high growth grades
Insider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells $20,528,940.00 in Stock
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility
Small-Cap healthcare stocks ranked by quant ratings after earnings season
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of “Hold” from Brokerages
Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates
Ironwood Pharmaceuticals Non-GAAP EPS of -$0.01 misses by $0.02, revenue of $47.71M misses by $3.22M
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
Here are the major earnings before the open Wednesday
What's in Store for These 5 Medical Companies This Earnings Season?
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 5.6% – Here’s What Happened
IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock?
Ironwood Pharmaceuticals (NASDAQ:IRWD) & CytoDyn (OTCMKTS:CYDY) Critical Survey
Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption?
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Passes Above 200 Day Moving Average – Time to Sell?
Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026
Ironwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month High After Analyst Upgrade
Ironwood Pharma (IRWD) Surges on Strong FY26 Guidance and Pipeline Updates
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report?
Ironwood Pharmaceuticals (NASDAQ:IRWD) versus Citius Pharmaceuticals (NASDAQ:CTXR) Critical Analysis
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of “Hold” by Brokerages
Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?